Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07515014 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of E6742 in Participants With Systemic Lupus Erythematosus

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 41 → 54 locationsv6
  2. Trial sites expanded: 28 → 41 locationsv5
  3. Trial sites expanded: 22 → 28 locationsv4
  4. Trial sites expanded: 17 → 22 locationsv3
  5. Recruitment opened Trial sites expanded: 2 → 17 locationsv2 Show 1 more changeShow less
    • Trial sites expanded: 2 → 17 locations
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Biogen
92 trials monitored
See 7 trials at risk
Lupus (SLE)
651 trials monitored
See 25 trials at risk
The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) with a low dose of oral corticosteroids (OCS) (prednisone or equivalent) at Week 24 in participants with systemic lupus erythematosus (SLE).
Trial Details
NCT Number NCT07515014
Lead Sponsor Eisai Co., Ltd.
Conditions Systemic Lupus Erythematosus
Enrollment 256 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov